Prima BioMed updates CVac development program

Clinical trial focus on second-remission ovarian cancer patient

13-Nov-2013 - Prima BioMed Ltd provided significant updates to its CVac™ clinical development program. Prima previously reported all progression-free survival data from its CAN-003 protocol, a 63-patient phase 2 trial of CVac for the treatment of epithelial ovarian cancer in remission after standard first-or ...

Novel method for treating ovarian cancer

11-Aug-2011 - The Fraunhofer Institute for Cell Therapy and Immunology IZI supports the Australian company Prima BioMed Ltd. intests and approvals regarding a novel therapeutic method for treating ovarian cancer. Prima BioMed Ltd. is developing an autologous (the body's own) immune therapy for the treatment of ...

Prima Biomed and Bioceros announce licensing agreement for Cripto-1 cancer immunotherapy treatment

09-Sep-2010 - Prima BioMed Ltd announced that its subsidiary company, Oncomab Pty Ltd has entered into a licensing agreement for the development of a Cripto-1 cancer monoclonal antibody (mAB) with Bioceros. The licensing agreement paves the way for the further development of Oncomab’s technology to create a ...

Prima BioMed enters agreement with Fraunhofer Institute for Cell Therapy and Immunology to produce cancer vaccine

01-Jun-2010 - Prima BioMed enters an agreement with Fraunhofer Institute for Cell Therapy and Immunology to produce a cancer vaccine. The agreement represents a crucial step in the development and production of CVac™ in Europe. Establishment of a subsidiary in Leipzig is envisioned. The preparation for ...